Intercept Pharmaceuticals Appoints Lisa Bright as Head of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Intercept Pharmaceuticals Appoints Lisa Bright as Head of Europe

NEW YORK and LONDON, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals (Nasdaq: ICPT ), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, announced today the appointment of Lisa Bright as Senior Vice President and Head of Europe, effective November 17, 2014. Ms. Bright will be a member of the Intercept senior management team and will spearhead Intercept's European operations based in London as the company prepares for the first indication approval and launch of obeticholic acid (OCA).

A seasoned executive who brings more than 25 years of biotech and pharmaceutical industry experience, Ms. Bright comes to Intercept from Gilead Sciences where she held positions of increasing responsibility, including Vice President, Northern Europe, and most recently Vice President, Head of Sovaldi Launch Planning for Europe, Asia, Middle East and Australasia and Vice President, Head Government Affairs for Europe, Middle East and Australasia. Ms. Bright's leadership of Sovaldi's European launch contributed to the most successful product launch in pharmaceutical history.

Ms. Bright joined Gilead as General Manager, UK & Ireland in 2008. Prior to that, she held a range of senior leadership positions over a 10-year tenure at GSK, including Vice President & Managing Director of GSK's New Zealand operations and Vice President and Head of Sales, UK.

"Lisa brings a highly relevant track record of performance in managing high growth organizations, leading product launches in the chronic liver disease therapeutic space, and advancing key stakeholder relationships internationally," said Mark Pruzanski, M.D., Chief Executive Officer. "We are thrilled she is joining Intercept's senior management team as we prepare for our anticipated commercial launch of OCA in the U.S. and Europe."

"I'm really excited to join Mark and his team to continue building Intercept into a leading biotech company tackling neglected liver diseases such as PBC and NASH," said Ms. Bright. "I look forward to continuing to work with clinicians, health care systems and community groups to ensure that innovative medicines get to patients who often have no other therapeutic option as quickly as possible." 

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent chronic liver and intestinal diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), and primary sclerosing cholangitis (PSC). OCA has received Fast Track Designation in the United States and orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Several large, randomized, controlled studies of OCA in the treatment of chronic liver disease have been completed. These include Intercept's Phase 3 POISE trial for the treatment of patients with PBC and the FLINT trial for the treatment of patients with NASH. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma. For more information about Intercept, please visit the company's website at: www.interceptpharma.com .

Safe Harbor Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Intercept ' s plans to commercialize OCA and expand its operations into Europe, and the timing therefor. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of important risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the initiation, cost, timing, progress and results of our development activities, preclinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approval of OCA, INT-767, INT-777 and any other product candidates we may develop, particularly the possibility that regulatory authorities may require clinical outcomes data (and not just results based on achievement of a surrogate endpoint) as a condition to any marketing approval for OCA, and any related restrictions, limitations, and/or warnings in the label of any approved product candidates; our plans to research, develop and commercialize our product candidates; the election by our collaborators to pursue research, development and commercialization activities; our ability to attract collaborators with development, regulatory and commercialization expertise; our ability to obtain and maintain intellectual property protection for its product candidates; our ability to successfully commercialize our product candidates; the size and growth of the markets for our product candidates and our ability to serve those markets; the rate and degree of market acceptance of any future products; the success of competing drugs that are or become available; regulatory developments in the United States and other countries; the performance of third-party suppliers and manufacturers; our need for and ability to obtain additional financing; our estimates regarding expenses, future revenues and capital requirements and the accuracy thereof; our ability to retain key scientific or management personnel; and other factors discussed under the heading "Risk Factors" contained in our annual report on Form 10-K for the year ended December 31, 2013 filed on March 14, 2014 as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intercept undertakes no duty to update this information unless required by law.

Intercept Pharmaceuticals: Barbara Duncan or Senthil Sundaram +1-646-747-1000 Media inquiries: Chantal Beaudry or Christopher Frates Lazar Partners + 1-212-867-1762

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 92

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 188

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 227

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 62

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 74

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 60

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 117

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Marelli’s Two Awards Put Practical Auto Tech in Focus

Updated Category News Views 89

Two trophies in Novi do not fill an order book, but Marelli’s latest pair says something useful about where automotive suppliers are trying to earn their keep. The company collected a 2026 Automotive News PACE Award for HorizonView and a PACE Pilot Award for Affordable 5G RedCap at the November 17 ceremony. One is already deployed in production; the other is a...

Continue Reading
Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 83

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading

Top 5 Most Recently Viewed Articles

UGREEN's NAS Launch: Is AI the Game-Changer or Just Hype?

Updated Category News Views 227

UGREEN announced its flagship AI NAS models on February 17, 2026, aiming to redefine private cloud data management with an active approach. Traders perked up when they heard about the iDX Series—specifically the UGREEN NASync iDX6011 and its Pro version. But here's where you should be asking tough questions: Can UGREEN really deliver amidst a crowded tech space? The...

Continue Reading
LRT Company Introduces $17 Million Senior Living Investment Deal

Updated Category News Views 133

LRT Company Unveils Innovative Senior Living Project In a significant move for the senior living sector, LRT Company has rolled out the LRT Hardeeville Senior Living DST. This cash-based offering aims to generate $17 million from accredited investors and presents a compelling opportunity to meet the growing demand for quality senior housing. Offering Details The LRT...

Continue Reading
Innovative Advances in Dendritic Cell Therapies for Cancer

Updated Category News Views 287

Groundbreaking Insights in Cancer Immunotherapy In an exciting development, Northwest Biotherapeutics (OTCQB: NWBO) plans to showcase significant advancements at the upcoming Frontiers in Cancer Immunotherapy Conference. Dr. Marnix Bosch, the company's Chief Technical Officer, will present a discussion titled "Next Generation Dendritic Cell Treatments to Improve...

Continue Reading
Scooter's Coffee: Celebrated among Leading US Franchises

Updated Category News Views 303

Scooter's Coffee Receives Esteemed Recognition in Franchise Rankings With over 850 locations spread across multiple states, Scooter's Coffee has secured a prominent position as one of the leading drive-thru coffee brands in the United States. The brand has been recognized for its impressive growth and community engagement, establishing itself as a favorite among coffee...

Continue Reading
Viatris Investors Urged to Act – Important Legal Deadline Approaches

Updated Category News Views 355

Viatris Class Action Lawsuit Updates Kahn Swick & Foti, LLC offers a timely reminder to investors who have suffered losses exceeding $100,000 in Viatris Inc. (NASDAQ: VTRS). The firm urges affected individuals to take note of the approaching deadline for lead plaintiff applications in light of the ongoing securities class action lawsuit involving the company....

Continue Reading